Viral Hepatitis Wrap-up and Debrief

Viral Hepatitis Wrap-up and Debrief
From The Liver Meeting 2026 (266 posters of distinction across HBV, HCV, and HDV), the biggest storylines were on the hepatitis B cure front: bepirovirsen trial data showed durable functional cure out to 15 months with stopping rules now defined, PBGENE-HBV gene-editing therapy drove durable pgRNA loss in 92% of patients, and expanded “why not treat?” guideline momentum pushed toward treating all HBV DNA- or HBsAg-positive patients. On hepatitis delta, new consensus calls for universal HDV antibody screening in all HBsAg-positive individuals with reflex RNA testing, while real-world data showed testing rates remain stubbornly low and that even resolved HDV infection carries double the long-term liver-event risk of HBV alone — alongside broader findings that global HBV mortality has stayed flat despite falling incidence, underscoring persistent gaps in diagnosis and linkage to care.
